FRAS1

Across TCGA pan-cancer cohorts, FRAS1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated FRAS1 data layer compared with 22 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher FRAS1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated FRAS1 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LUAD show a favorable association.

CCRCC, PDAC, and LUAD are the cancer types where FRAS1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	III,IV	0.795	0.295	<.001	38	view →
PDAC	OS	Quartile	All	0.355	0.688	.001	24	view →
LUAD	DFS	Quartile	All	0.822	0.536	.043	5	view →
LSCC	OS	Quartile	III,IV	0.972	0.563	.033	4	view →
UCEC	OS	Median	All	0.861	0.983	.021	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

FRAS1–CCRCC (DFS)

Open the CCRCC breakdown →